statistiche ricercatore

Continente	#
AS - Asia	774
NA - Nord America	739
EU - Europa	264
SA - Sud America	94
AF - Africa	8
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.880

Nazione	#
US - Stati Uniti d'America	713
CN - Cina	266
SG - Singapore	264
BR - Brasile	78
HK - Hong Kong	73
IT - Italia	51
GB - Regno Unito	50
KR - Corea	48
BD - Bangladesh	43
VN - Vietnam	40
FI - Finlandia	35
RU - Federazione Russa	26
SE - Svezia	26
DE - Germania	23
CA - Canada	14
LT - Lituania	13
FR - Francia	11
AR - Argentina	7
IN - India	7
IQ - Iraq	6
NL - Olanda	6
ZA - Sudafrica	5
IE - Irlanda	4
PE - Perù	4
IL - Israele	3
JP - Giappone	3
MX - Messico	3
PK - Pakistan	3
UA - Ucraina	3
AL - Albania	2
CR - Costa Rica	2
EC - Ecuador	2
HN - Honduras	2
LA - Repubblica Popolare Democratica del Laos	2
NI - Nicaragua	2
OM - Oman	2
PA - Panama	2
PL - Polonia	2
PT - Portogallo	2
QA - Qatar	2
TR - Turchia	2
AE - Emirati Arabi Uniti	1
AM - Armenia	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BG - Bulgaria	1
BO - Bolivia	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
HU - Ungheria	1
IS - Islanda	1
KG - Kirghizistan	1
LK - Sri Lanka	1
LV - Lettonia	1
MA - Marocco	1
NP - Nepal	1
PH - Filippine	1
PS - Palestinian Territory	1
PY - Paraguay	1
RO - Romania	1
SI - Slovenia	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
SY - Repubblica araba siriana	1
TN - Tunisia	1
TW - Taiwan	1
VE - Venezuela	1
Totale	1.879

Nome	#
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients	204
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes	172
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia	170
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells	154
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients	153
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside	152
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells	151
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS	149
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression	148
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation	146
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines	145
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia	136
Totale	1.880

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2022/2023	89	0	0	0	4	9	20	1	14	16	3	8	14
2023/2024	113	3	5	6	21	17	11	21	2	5	0	15	7
2024/2025	586	10	3	0	37	109	87	15	30	91	15	98	91
2025/2026	952	85	87	122	106	110	41	91	21	57	90	43	99
2026/2027	140	36	82	22	0	0	0	0	0	0	0	0	0
Totale													1.880